Koen Willekens1, Luís Abegão Pinto, Evelien Vandewalle, Ingeborg Stalmans, Peter Stalmans. 1. *Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium; and †Department of Ophthalmology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal and Institute of Pharmacology and Neurosciences, Faculty of Medicine, Lisbon University, Lisbon, Portugal.
Abstract
PURPOSE: To determine the efficacy and safety of ocriplasmin for vitreomacular traction (VMT) resolution and to study changes in optic disk and peripapillary region. METHODS: Retrospective, single-center, observational case series. In 38 eyes with VMT (10 with concomitant full-thickness macular hole), determined by optical coherence tomography, a single intravitreal injection of ocriplasmin was administered. Baseline ocular characteristics included the presence/absence of epiretinal membrane, lens status, and vitreomacular adhesion size. Spectral domain optical coherence tomography and Heidelberg retinal tomography were performed at baseline and follow-up visits. RESULTS: A total of 71.1% of eyes treated with ocriplasmin had VMT resolution, improving to 83.9% after applying MIVI-TRUST selection criteria. A total of 90% of eyes with full-thickness macular hole showed VMT resolution, with 40% of those achieving full-thickness macular hole closure. Subretinal fluid in the macular region was observed in 36.8% of eyes 1 day after injection, and all cleared spontaneously by Day 42. A significant difference was observed in cup/disk area ratio between patients who achieved VMT resolution and patients who did not. CONCLUSION: Careful patient selection improves ocriplasmin efficacy. Transient optic disk morphology changes such as decreased cup/disk area ratio may occur in patients without VMT resolution.
PURPOSE: To determine the efficacy and safety of ocriplasmin for vitreomacular traction (VMT) resolution and to study changes in optic disk and peripapillary region. METHODS: Retrospective, single-center, observational case series. In 38 eyes with VMT (10 with concomitant full-thickness macular hole), determined by optical coherence tomography, a single intravitreal injection of ocriplasmin was administered. Baseline ocular characteristics included the presence/absence of epiretinal membrane, lens status, and vitreomacular adhesion size. Spectral domain optical coherence tomography and Heidelberg retinal tomography were performed at baseline and follow-up visits. RESULTS: A total of 71.1% of eyes treated with ocriplasmin had VMT resolution, improving to 83.9% after applying MIVI-TRUST selection criteria. A total of 90% of eyes with full-thickness macular hole showed VMT resolution, with 40% of those achieving full-thickness macular hole closure. Subretinal fluid in the macular region was observed in 36.8% of eyes 1 day after injection, and all cleared spontaneously by Day 42. A significant difference was observed in cup/disk area ratio between patients who achieved VMT resolution and patients who did not. CONCLUSION: Careful patient selection improves ocriplasmin efficacy. Transient optic disk morphology changes such as decreased cup/disk area ratio may occur in patients without VMT resolution.
Authors: Haifa A Madi; Richard J Haynes; Diana Depla; Morten D de la Cour; Sarit Lesnik-Oberstein; Mahi M K Muqit; Niall Patton; Nick Price; David H W Steel Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-06-08 Impact factor: 3.117
Authors: Arshad M Khanani; Ryan N Constantine; Koenraad H Blot; Benedicte Lescrauwaet; Peter Szurman Journal: Acta Ophthalmol Date: 2020-12-26 Impact factor: 3.761
Authors: Bart Jonckx; Michael Porcu; Aurelie Candi; Isabelle Etienne; Philippe Barbeaux; Jean H M Feyen Journal: J Ophthalmol Date: 2017-10-29 Impact factor: 1.909